RxDoctor Payments Data

Robert Calcote, MD

Dermatology · Huntsville, ALNPI 1730243502

Payments from drug & device makers

$1,968in general payments, 2019–2025

Across 93 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$341
  • AbbVie$301
  • LEO Pharma Inc.$245
  • Sanofi$205
  • Novartis$172
  • Sun Pharmaceutical Industries Inc.$160
  • plus $544 from 12 others

What the payments were for

  • Food & beverage$1,968100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,968 in reported general payments places this provider in the 35th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$606,492
Medicare patients
1,248
Services billed
8,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab36$239,333
Cosentyx Unoready PenSecukinumab11$124,159
AdbryTralokinumab-Ldrm28$104,352
Dupixent PenDupilumab27$103,064
OtezlaApremilast21$102,428
Dupixent SyringeDupilumab11$40,374
Doxycycline Ir-DrDoxycycline Monohydrate30$29,188
Clobetasol Propionate139$8,545
Clobetasol EmollientClobetasol Propionate/Emoll83$6,708
Metronidazole95$6,636
Doxycycline Hyclate165$6,376
Ketoconazole259$5,947
Clindamycin Phosphate71$3,159
Azelaic Acid15$2,501
Betamethasone Dipropionate31$2,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$245$104,35228 claims
AmgenOtezla$53$102,42821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 168 dermatology providers in Alabama.

Other dermatology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →